In Situ conversion of melanoma lesions into autologous vaccine by intratumoral injections of α-gal glycolipids

Cancers

Volumn 2, Issue 2, 2010, Pages 773-793

  Galili, Uri ^a   Albertini, Mark R ^b   Sondel, Paul M ^b   Wigglesworth, Kim ^a   Sullivan, Mary ^a   Whalen, Giles F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

gal glycolipids; 1,3 galactosyltransferase; Anti gal antibody; Antigen presenting cells; Fc ; Melanoma immunotherapy; Receptors

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA GALACTOSYLCERAMIDE; FC RECEPTOR; MELANOMA ANTIGEN; MELANOMA VACCINE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; DISTANT METASTASIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MELANOMA; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VIRAL GENE THERAPY;

EID: 79952275873     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020773     Document Type: Review

References (64)

1. Dunn, G.P.; Bruce, A.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
2. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411, 380-384.
3. Weir, B.A.; Woo, M.S.; Getz, G.; Perner, S.; Ding, L.; Beroukhim, R.; Lin, W.M.; Province, M.A.; Kraja, A.; Johnson, L. A.; et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450, 893-898.
4. Wood, L.D.; Parsons, W.D.; Jones, S.; Lin, J.; Sjoblom, T.; Barber, T.; Parmigiani, G.; Velculescu, V.; Kinzler, K.W.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318, 1108-1113.
5. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pagès, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
6. Thor Straten, P.; Becker, J.C.; Guldberg, P.; Zeuthen, J. In situ T cells in melanoma. Cancer Immunol. Immunother. 1999, 48, 386-395.
7. Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H. Schlienger, K. Liebman, M.N.; Rubin, S.C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203-213.
8. Clemente, C.G.; Mihm Jr, M.C.; Bufalino, R.; Zurrida, S.; Collini, P.; Cascinelli, N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77, 1303-1310.
9. Levy R.A. perspective on monoclonal antibody therapy: where we have been and where we are going. Semin. Hematol. 2000, 37, 43-46.
10. Kwak, L.W. Translational development of active immunotherapy for hematological malignancies. Semin. Oncol. 2003, 30, 17-22.
11. Huang, A.Y.; Golumbek, P.; Ahmadzadeh, M.; Jaffee, E.; Pardoll, D.; Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264, 961-965.
12. Zinkernagel, R.M; Ehl, E.; Aichele, P.; Kündig, T.; Hengartner, H. Antigen localization regulates immune responses in a dose and time dependent fashion: A geographical view of immune reactivity. Immunol. Rev. 1997, 156, 199-209.
13. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18, 767-811.
14. Khong, H.T.; Restifo, N.P. Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat. Immunol. 2002, 3, 999-1005.
15. Unkeless, J.C. Functional heterogeneity of human Fc receptors for immunoglobulin G. J. Clin. Inves. 1989, 83, 355-361.
16. Ravetch, J.V.; Clynes, R.A. Divergent roles for Fc receptors and complement In vivo. Annu. Rev. Immunol. 1998, 16, 421-432.
17. Fanger, N.A.; Wardwell, K.; Shen, L.; Tedder, T.F.; Guyre, P.M. Type I (CD64) and Type II (CD32) Fc receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 1996, 157, 541-548.
18. Stoner, R.D.; Terres, G. Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody. J. Immunol. 1963, 91, 761-770.
19. Manca, F.; Fenoglio, D.; LiPira, G.; Kunkl, A.; Celada, F. Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med. 1991, 17, 37-48.
20. Gosselin, E.J.; Wardwell, K.; Gosselin, D.R.; Alter, N.; Fisher, J.L.; Guyre, P.M. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 1992, 149, 3477-3481.
21. Celis, E.; Abraham, K.G.; Miller, R.W. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 1987, 7, 563-568.
22. Villinger, F.; Mayne, A.E.; Bostik, P.; Mori, K.; Jensen, P.E.; Ahmed, R.; Ansari, A.A. Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J. Virol. 2003, 77, 10-24.
23. Regnault, A.; Lankar, D.; Lacabanne, V.; Rodriguez, A.; Théry, C.; Rescigno, M.; Saito, T.; Verbeek, S.; Bonnerot, C.; Ricciardi-Castagnoli, P.; Amigorena, S. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 1999, 189: 371-380.
24. Berlyn, K.A.; Schultes, B.; Leveugle, B.; Noujaim, A.A.; Alexander, R.B.; Mann, D.L. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin. Immunol. 2001, 101, 276-283.
25. Rafiq, K.; Bergtold, A.; Clynes, R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 2002, 110, 71-79.
26. Dhodapkar, K.M.; Krasovsky, J.; Williamson, B.; Dhodapkar, M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 2002, 195, 125-133.
27. Groh, V.; Li, Y.Q.; Cioca, D.; Hunder, N.N.; Wang, W.; Riddell, S.R.; Yee, C.; Spies, T. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl. Acad. Sci. USA 2005, 102, 6461-6466.
28. Galili, U.; Rachmilewitz, E.A.; Peleg, A.; Flechner, I. A unique natural human IgG antibody with anti-?-galactosyl specificity. J. Exp. Med. 1984, 160, 1519-1531
29. Galili, U.; Mandrell, R.E.; Hamadeh, R.M.; Shohet, S.B.; Griffis, J.M. Interaction between human natural anti-a-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 1988, 56, 1730-1737.
30. Galili, U.; Macher, B.A.; Buehler, J.S.; Shohet, B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1→3)-linked galactose residues. J. Exp. Med. 1985, 16, 573-582.
31. Galili, U.; Buehler, J.; Shohet, S.B.; Macher, B.A. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J. Exp. Med. 1987, 165, 693-704.
32. Galili, U.; Clark, M.R.; Shohet, S.B.; Buehler, J.; Macher, B.A. Evolutionary relationship between the anti-Gal antibody and the Galα1→3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 1987, 84, 1369-1373.
33. Galili, U.; Shohet, S.B.; Kobrin, E.; Stults, C.L.M.; Macher, B.A. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 1988, 263, 17755-17762.
34. Galili, U. Evolution and pathophysiology of the human natural anti-Gal antibody. Springer Semin ImmunopathoL. 1993, 15, 155-171.
35. Macher, B.A.; Galili, U. The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochem. Biophys. Acta 2008, 1780, 75-88.
36. Galili, U.; Swanson, K. Gene sequences suggest inactivation of a1,3 galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc. Natl. Acad. Sci. USA 1991, 88, 7401-7404.
37. Galili, U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotranplantation in humans. Immunol. Today 1993, 14, 480-482.
38. Good, A.H.; Cooper, D.K.; Malcolm, A.J.; Ippolito, R.M.; Koren, E.; Neethling, F.A.; Ye, Y.; Zuhdi, N.; Lamontagne, L.R. Identification of carbohydrate structures which bind human anti-porcine antibodies: implication for discordant xenografting in man. Transplant Proc. 1992, 24, 559-562.
39. Sandrin, M.; Vaughan, H.A.; Dabkowski, P.L.; McKenzie, I.F.C. Anti-pig IgM antibodies in human serum react predominantly with Gala1-3Gal epitopes. Proc. Natl. Acad. Sci. USA 1993, 90, 11391-11395.
40. Collins, B.H.; Cotterell, H.A.; McCurry, K.R.; Alvarado, C.G.; Magee, J.C.; Parker, W.; Platt, J.L. Cardiac xenografts between primate species provide evidence of the?-galactosyl determinant in hyperacute rejection. J. Immunol. 1995, 154, 5500-5510.
41. LaTemple, D.C.; Henion, T.R.; Anaraki, F.; Galili, U. Synthesis of a-galactosyl epitopes by recombinant a1,3galactosyltransferase for opsonization of human tumor cell vaccines by anti-Gal. Cancer Res. 1996, 56, 3069-3074.
42. Galili, U.; LaTemple, D.C. The natural anti-Gal antibody as a universal augmenter of autologous vaccine immunogenicity. Immunol. Today 1997, 18, 281-285.
43. Thall, A.D.; Maly, P.; Lowe, J.B. Oocyte Galα1-3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J. Biol. Chem. 1995, 270, 21437-21442.
44. Abdel-Motal, U.M.; Wang, S.; Lu, S.; Wigglesworth, K.; Galili, U. Increased immunogenicity of HIV gp120 engineered to express Galα1-3Galβ1-4GlcNac-R epitopes. J. Virol. 2006, 80, 6943-6951.
45. Abdel-Motal, U.M.; Guay, H.M.; Wigglesworth, K.; Welsh, R.M.; Galili, U. Increased immunogenicity of influenza virus vaccine by anti-Gal mediated targeting to antigen presenting cells. J. Virol. 2007, 81, 9131-9141.
46. Chen, Z.C.; Tanemura, M.; Galili, U. Synthesis of α-gal epitopes (Galα1-3Galß1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris. Glycobiology 2001, 11, 577-586.
47. Abdel-Motal, U.M.; Wigglesworth, K.; Galili, U. Mechanism for increased immunogenicity of vaccines that form In vivo immune complexes with the natural anti-Gal antibody. Vaccine 2009, 27, 3072-3082.
48. LaTemple, D.C.; Abrams, J.T.; Zhang, S.U.; Galili, U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knock out mice for α1,3galactosyltranferase. Cancer Res. 1999, 59, 3417-3423.
49. Deriy, L.; Ogawa, H.; Gao, G.; Galili, U. In vivo targeting of vaccinating tumor cells to antigen presenting cells by a gene therapy method with adenovirus containing the α1,3galactosyltransferase gene. Cancer Gene Ther. 2005, 12, 528-539.
50. Rossi, G.R.; Mautino, M.R.; Unfer, R.C.; Seregina, T.M.; Vahanian, N.; Link, C.J. Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes. Cancer Res. 2005, 65, 10555-10561.
51. Gorelik, E.; Duty, L.; Anaraki, F.; Galili, U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3galactosyltransferase gene transfection. Cancer Res. 1995, 55, 4168-4173.
52. Galili, U.; Wigglesworth, K.; Abdel-Motal, U.M. Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J. Immunol. 2007, 178, 4676-4687.
53. Abdel-Motal, U.M.; Wigglesworth, K.; Galili, U. Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol. Immunother. 2009, 58, 1545-1556.
54. Eto, T.; Iichikawa, Y.; Nishimura, K.; Ando, S.; Yamakawa, T. Chemistry of lipids of the posthemolytic residue or stroma of erythrocytes. XVI. Occurance of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes in rabbit. J. Biochem. (Tokyo) 1968, 64, 205-213.
55. Stellner, K.; Saito, H.; Hakomori, S. Determination of aminosugar linkage in glycolipids by methylation. Aminosugar linkage of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen. Arch. Biochem. Biophys. 1973, 133, 464-472.
56. Dabrowski, U.; Hanfland, P.; Egge, H.; Kuhn, S.; Dabrowski, J. Immunochemistry of I/i-active oligo- and polyglycosylceramides from rabbit erythrocyte membranes. Determination of branching patterns of a ceramide pentadecasaccharide by 1H nuclear magnetic resonance. J. Biol. Chem. 1984, 259, 7648-7651.
57. Egge, H.; Kordowicz, M.; Peter-Katalinic, J.; Hanfland, P. Immunochemistry of I/i-active oligo- and polyglycosylceramides from rabbit erythrocyte membranes. Characterization of linear, di-, and triantennary neolactoglycosphingolipids. J. Biol. Chem. 1985, 260, 4927-4935.
58. Hanfland, P.;; Kordowicz, M.; Peter-Katalinic, J.; Egge, H.; Dabrowski, J.; Dabrowski, U. Structure elucidation of blood group B-like and I-active ceramide eicosa- and pentacosasaccharides from rabbit erythrocyte membranes by combined gas chromatography-mass spectrometry; electron-impact and fast-atom-bombardment mass spectrometry; and two-dimensional correlated, relayed-coherence transfer, and nuclear Overhauser effect 500-MHz 1H-NMR spectroscopy. Carbohydr. Res. 1988, 178, 1-21.
59. Honma, K.; Manabe, H.; Tomita, M.; Hamada, A. Isolation and partial structural characterization of macroglycolipid from rabbit erythrocyte membranes. J. Biochem. (Tokyo) 1981, 90, 1187-1196.
60. Ogawa, H.; Galili, U. Profiling terminal N-acetyllactoamines of glycans on mammalian cells by an immuno-enzymatic assay. Glycoconjugate J. 2006, 23: 663-674.
61. Pan, P.Y.; Li, Y.; Li, Q.; Gu, P.; Olivier, M.; Thung, S.; Shu-Hsia, C. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol. Immunother. 2004, 53, 17-25.
62. Manches, O.; Plumas, J.; Lui, G.; Chaperot, L.; Molens, J.P.; Sotto, J.J.; Bensa, J.C.; Galili, U. Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy with autologous tumor cells. Haematologica 2005, 90, 625-634.
63. Turk, M.J.; Guevara-Patino, J.A.; Rizzuto, G.A.; Engelhorn, M.E.; Houghton, A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 2004, 200, 771-782.
64. Galili, U.; Tibell, A.; Samuelsson, B.; Rydberg, B.; Groth, C.G. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995, 59, 1549-1556.